Mesoblast MESO
NASDAQ MESO
$17.32 +0.18 (+1.05%)
At close: Sep 4, 2026 · 4:00 PM EDT

Mesoblast (MESO) Non-Current Debt (2018)

Mesoblast (MESO) posted Non-Current Debt of -$149.3 million for Q4 2025, down 192.43% sequentially from $161.6 million in Q2 2025, and down 7.0% YoY from -$160.6 million in Q4 2024.

Analysis

Mesoblast (MESO) Non-Current Debt (2018) Analysis & Trends

Mesoblast has reported Non-Current Debt for 8 years, with the latest figure at -$149.3 million in Q4 2025.

  • Quarterly Non-Current Debt fell 7.0% year-over-year to -$149.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$149.3 million (down 7.0% YoY) and the FY2025 annual result came in at $161.6 million, up 60.77% from the prior year.
  • Non-Current Debt declined to -$149.3 million in Q4 2025 per MESO's latest filing, from $161.6 million in the prior quarter.
  • Over five years, Non-Current Debt peaked at $161.6 million in Q2 2025 and troughed at -$149.3 million in Q4 2025.
  • A 5-year average of $13.5 million and a median of $42.7 million in 2021 frame the typical range for Non-Current Debt.
  • The sharpest annual moves came in 2022 and 2023: Non-Current Debt jumped 123.21% in 2022, then slumped 234.31% in 2023.
  • Over 5 years, Non-Current Debt stood at $86.5 million in 2021, then plunged by 233.71% to -$115.7 million in 2022, then decreased by 6.29% to -$123.0 million in 2023, then declined by 13.46% to -$139.5 million in 2024, then retreated by 7.0% to -$149.3 million in 2025.
  • According to Business Quant data, Non-Current Debt over the past three periods registered -$149.3 million, $161.6 million, and -$139.5 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 1.99 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 591.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 882.16 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn -
8 Royalty Pharma 28.45 Bn 27.61 Bn - 8.96 Bn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 546.77 Mn
10 Mesoblast 2.24 Bn 2.14 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2018 61.16 Mn
Jun 30, 2018 59.40 Mn
Mar 31, 2018 31.42 Mn